secwatch.observer — SEC 8-K summary
======================================

Issuer:     Terns Pharmaceuticals, Inc. (TERN)
CIK:        0001831363
Form:       8-K
Filed at:   2023-01-05T23:59:59+00:00
Accession:  0000950170-23-000233
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Terns Pharmaceuticals details 2023 clinical milestones; cash runway to 2026
---------------------------------------------------------------------------

- Plan to initiate US Phase 1 trial for TERN-701 (CML) in H2 2023; top-line readouts 2024. Due to IRA, will not seek US approval for Ph+ ALL.
- Phase 2a DUET trial of TERN-501 (NASH) expects enrollment completion Q1 2023, top-line data Q3 2023; first combo of THR-β and FXR agonist.
- Obesity program TERN-601 (GLP-1 agonist) Phase 1 start H2 2023, top-line data in 2024; preclinical data to be published.
- Cash runway extended to 2026: $293M adjusted cash includes $106M net from Dec 2022 equity offering; excludes potential collaborations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831363/000095017023000233/0000950170-23-000233-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831363/000095017023000233/tern-20230105.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-000233

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer